| Background Schizophrenia is a cause of unknown,severe chronic mental illness,the world’s about 0.5-1% of the population suffered by the bitter.In recent years,studies have found that even if the clinical application of a wide range of atypical antipsychotics,but there are still some patients can not adhere to the whole course of antipsychotics treatment,resulting in the recurrence of the disease.Studies have shown that psychotherapy can add a small to medium-sized effect on the basis of drug therapy,providing a viable treatment for patients with mental illness.The Metacognitive Training Program(MCT)improves the patient’s clinical rehabilitation and prognosis by improving the patient’s understanding of psychotic symptoms while improving the delusions of schizophrenic patients.Therefore,through the further study of metacognitive training program,it will provide a new theoretical basis and technical support for the improvement of symptoms and overall prognosis of schizophrenic patients.Objectives 1.To explore the effect of metacognitive training combined with olanzapine on clinical symptoms,insight and drug compliance in patients with schizophrenia.2.To explore the influence of metacognitive training combined with olanzapine on cognition and social cognitive dysfunction in schizophrenic patients.Methods 1.A case-control study was conducted to collect 107 patients with schizophrenia based on the diagnostic criteria for schizophrenia in the tenth edition(ICD-10)of the International Statistical Classification of Diseases and Related Health Problems.The patients were assigned to meta-cognitive training group(ie,study group,n=54)and olanzapine treatment group(ie,control group,n=53)using random number table method.The patients in the study group were treated with olanzapine tablets and meta-cognitive training.The control group was treated with olanzapine tablets.Both groups were given supportive psychotherapy for 4 weeks.2.General data were collected for all subjects and assessed by PANSS,ITAQ,MARS BCIS,IPSAQ,FPRT scales at baseline and after treatment.3.All data were analyzed by SPSS19.0 statistical software.Measurement data using independent sample t test,paired t test.Bilateral P<0.05 for the difference was statistically significant.The results are expressed as mean ± standard deviation(x± s).Results 1.At 4 weeks after treatment,the study group and the control group compared with their baseline,PANSS score and each subscale and IPSAQ score were lower than the control group,the difference was statistically significant(P<0.05),MARS score,ITAQ,BCIS and FPRT scores were higher than the control group,the difference was statistically significant(P <0.05).2.There was no significant difference in the scores of the study group and the control group at baseline(P>0.05).At the end of 4 weeks,the PANSS score and the subscale scores and IPSAQ scores of the study group were significantly lower than those of the control group(P<0.05).The scores of MARS score,ITAQ score,BCIS and FPRT in the study group were significantly higher than those in the control group(P<0.05).3.At the end of 4 weeks,the difference between PANSS score and factor score,IPSAQ score and baseline was significantly lower than that of the study group,the difference was statistically significant(P<0.05).The difference between MARS,ITAQ,BCIS and FPRT scores and baseline was significantly higher in the study group than in the control group(P<0.05).Conclusions 1.Metacognitive training as an adjunctive treatment of drug therapy,can improve the clinical symptoms of schizophrenia and treatment compliance.2.Metacognitive training as an adjunctive treatment of drug therapy,can improve the prognosis of schizophrenic patients with cognitive strength,cognitive awareness and social cognitive function. |
PDF Full Text Request